Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 14, 2025
Management Tracks
Rui Santos Ivo elected as new chair at EMA
Plus: Jane Chung named CEO of Sutro after strategic review, and Richard Law becomes CBO at Haya
BioCentury | Feb 1, 2025
Data Byte
Safety of Alzheimer’s therapy again under scrutiny at EMA’s CHMP
Plus: Pfizer’s Tivdak gets CHMP nod, as Daiichi’s Dato-Dxd receives positive opinion in one indication, gets withdrawn in another
BioCentury | Aug 27, 2024
Deals
Deals Report: Selling assets to CBC and Mubadala, UCB turns China focus to innovation
Plus: A pair of ADC deals between Merck-Kelun, Adcendo-Multitude
BioCentury | May 17, 2024
Data Byte
FDA label expansions: Full approval for Tivdak in April
Plus: Tissue agnostic accelerated approval for Enhertu
BioCentury | Mar 28, 2024
Finance
Venture report: Liquidity coming for Boundless’ syndicate; plus Avenzo’s $150M round
As VC-backed start-ups continue to watch and wait for their IPO window, a large syndicate backs an oncology start-up with aspirations to go public
BioCentury | Mar 15, 2024
Data Byte
Enhertu top seller among five solid tumor ADCs
After surpassing Kadcyla in 2023 sales, the antibody-drug conjugate from AZ and Daiichi could be poised for more growth
BioCentury | Jan 9, 2024
Deals
Jan. 9 Quick Takes: Precision deal gets TG entry into autoimmune CAR T race
Plus: Pfizer’s, Genmab’s Tivdak gets priority review for full approval and more from Astellas, Cumulus, Pfizer and Innovent
BioCentury | Dec 7, 2023
Emerging Company Profile
GenFleet: building a fleet of first-in-class cancer and immune therapies
With its first regulatory submission filed in China, the biotech is setting its next sights on global first-in-class therapies
BioCentury | Sep 5, 2023
Deals
Sept. 5 Quick Takes: Moulder’s Zenas in regional deal with BMS for bispecific
Plus: Beam moves base editors into the clinic and updates on Star, Tivdak, Olema and Insmed’s Arikayce
BioCentury | Mar 10, 2023
Regulation
March 10 Quick Takes: FDA approves Pfizer’s nasal spray for migraine
Plus: $50M series B, new CMO for cross-border play Allorion and updates from Merck & Co., Intercept, Iktos and more
Items per page:
1 - 10 of 252